CCL20

CCL20 Full Name

chemokine (C-C motif) ligand 20

CCL20 Introduction

CCL20 (C-C motif chemokine ligand 20), also known as macrophage inflammatory protein-3 alpha (MIP-3α), has emerged as an important chemokine target in immunology, inflammatory disease research, and oncology. Many researchers and drug developers focus on CCL20 because abnormal immune-cell trafficking remains a major challenge in chronic inflammation, autoimmune disorders, and tumor progression. CCL20 is primarily expressed by epithelial cells, keratinocytes, dendritic cells, fibroblasts, and activated immune cells in response to inflammatory cytokines such as TNF-α and IL-17. Its biological activity is mainly mediated through the CCR6 receptor, forming the highly selective CCL20/CCR6 signaling axis that regulates the migration of Th17 cells, dendritic cells, B cells, and regulatory T cells into inflamed tissues. Structural studies using cryo-electron microscopy have significantly advanced the understanding of this pathway by revealing that CCL20 activates CCR6 through an unusual shallow extracellular binding pocket rather than the deep orthosteric binding mode observed in many class A GPCRs. Researchers identified the N-terminal D5 residue of CCL20 as a critical determinant for receptor activation, highlighting a unique allosteric mechanism that may support the future development of highly selective CCR6 antagonists and therapeutic antibodies.

The growing interest in CCL20 is closely linked to its central role in inflammatory and autoimmune diseases where persistent immune activation damages tissue integrity and reduces quality of life. Elevated CCL20 expression has been consistently observed in psoriasis, inflammatory bowel disease, rheumatoid arthritis, and psoriatic arthritis, where the chemokine drives recruitment of CCR6-positive inflammatory cells into affected tissues. In psoriasis, the IL-23/IL-17/CCL20 inflammatory loop is particularly important because activated keratinocytes release CCL20, which then attracts additional Th17 cells and amplifies chronic skin inflammation. This self-reinforcing cycle contributes to epidermal hyperplasia, immune-cell infiltration, and long-term disease recurrence. Recent structural and mechanistic studies further demonstrated that the CCL20/CCR6 axis may serve as a promising therapeutic target for interrupting pathogenic immune-cell migration. In addition, the discovery that atypical chemokine receptor ACKR4 can scavenge and internalize CCL20 has provided new insight into how chemokine gradients are balanced under physiological conditions. Dysregulation of this clearance system may contribute to excessive inflammatory signaling, making the CCL20–ACKR4 interaction increasingly relevant in immune homeostasis research.

Beyond inflammatory disorders, CCL20 is increasingly recognized as a critical mediator of tumor progression and immune remodeling within the tumor microenvironment. High CCL20 expression has been associated with breast cancer, colorectal cancer, liver cancer, pancreatic cancer, and several metastatic malignancies, where it contributes to angiogenesis, epithelial–mesenchymal transition (EMT), tumor-cell migration, invasion, and resistance to chemotherapy. Researchers have also observed that tumor-derived CCL20 can recruit immunosuppressive CCR6-positive regulatory T cells and tumor-associated macrophages, creating a microenvironment that enables cancer immune evasion. These findings are particularly important for patients who fail to respond to conventional immunotherapies, as targeting the CCL20/CCR6 signaling network may improve immune reactivation and therapeutic sensitivity. Experimental monoclonal antibodies and CCR6-targeted inhibitors are now being explored as potential next-generation immunomodulatory therapies. Because CCL20 links chronic inflammation with cancer progression, it is increasingly viewed not only as a biomarker for disease activity and prognosis, but also as a valuable therapeutic target for precision medicine and translational drug discovery.

Alternate Names for CCL20

CCL20; chemokine (C-C motif) ligand 20; SCYA20, small inducible cytokine subfamily A (Cys Cys), member 20; C-C motif chemokine 20; CKb4; exodus 1; LARC; MIP 3a; ST38; exodus-1

• 1.Matti C, et al.; CCL20 is a novel ligand for the scavenging atypical chemokine receptor 4.J Leukoc Biol. 2020, 107(6):1137-1154.
  2.Kwantwi LB, et al.; Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression. Bioengineered. 2021, 12(1):6923-6934.